Immunofluorescence-based reclassification of idiopathic membranoproliferative glomerulonephritis: Insights from a single-center cohort

Table 4 Therapeutic strategies, treatment response, and renal outcomes in immune complex-mediated membranoproliferative glomerulonephritis vs complement-mediated membranoproliferative glomerulonephritis by immunosuppressive regimen, n (%)

	IC-MPGN (n = 100)	C-MPGN (n = 28)	P value
Immunosuppressives	51 (51)	19 (67.8)
Steroids alone	35 (35)	8 (28.57)
CR	8 (22.9)	0 (0)	0.134
PR	13 (37.1)	4 (50)	0.692
ESKD	12 (34.2)	4 (50)	0.68
Mortality	2 (5.7)	0 (0)	0.99
Cyclophosphamide + steroids	16 (16)	11 (39.28)
CR	2 (12.5)	3 (27.3)	0.37
PR	6 (37.5)	4 (36.4)	0.99
ESKD	6 (37.5)	4 (36.4)	0.89
Mortality	2 (12.5)	0 (0)	0.49

Continuous variables were compared using the Mann-Whitney U test (or Student’s t-test for normally distributed data). Categorical variables were analyzed using χ² or Fisher’s exact test, as appropriate. CR: Complete remission; PR: Partial remission; ESKD: End-stage kidney disease; IC-MPGN: Immune complex-mediated membranoproliferative glomerulonephritis; C-MPGN: Complement-mediated membranoproliferative glomerulonephritis.